Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Moderna Stock Hit an All-Time High Today

By Joe Tenebruso - Jun 29, 2021 at 4:37PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Promising clinical trial results are prompting more governments to authorize the biotech's coronavirus vaccine.

What happened

Shares of Moderna (MRNA -5.83%) climbed 5% to a record closing high above $234 on Tuesday, with two positive developments contributing to the biotechnology company's gains.

So what

Moderna announced that its COVID-19 vaccine appears to provide protection against several new coronavirus strains, including the Delta variant that is spreading rapidly around the world. "These findings highlight the importance of continuing to vaccinate populations with an effective primary series vaccine," CEO Stephane Bancel said in a press release. 

A person is pointing to an upwardly sloping stock chart.

Moderna's stock price has soared in 2021. Image source: Getty Images.

Moderna also said that the government of India granted an Emergency Use Authorization for its COVID-19 vaccine in adults aged 18 years and older. "I want to thank the government of India for this authorization, which marks an important step forward in the global fight against the pandemic," Bancel said. "We are committed to making our COVID-19 vaccine available around the world." 

Now what

Moderna's vaccine has emerged as a vital weapon in the global battle against COVID-19. With the drug continuing to display a remarkable efficacy and safety profile, governments around the world are ramping up their purchases of the life-saving vaccine. Moderna's stock, in turn, has delivered fortune-building returns to investors along the way, including a 124% surge so far in 2021. And with effective coronavirus protection as important today as ever, more gains appear likely.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$148.78 (-5.83%) $-9.22

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
395%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.